Gynae BT 2017

PORTEC-1 trial (1990-1997)

Stage I intermediate risk (n=714): • grade 1 or 2 with ≥50% invasion • grade 2 or 3 with <50% invasion • TAH-BSO without lymphadenectomy

pelvic radiotherapy

46 Gy / 23# / 5 wks

R

no further treatment

Creutzberg et al, Lancet 2000